Cantargia Announces Early Results from Trial of Nadunolimab in MDS and AML

AI Briefing

• – Cantargia's Nadunolimab shows promising results in early trial for MDS and AML, company announces
• – Cantargia's Nadunolimab to be investigated in combination with best-in-class therapies for AML
• – Trial results to be presented at an upcoming medical conference